-

Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET.

To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion’s Investor Relations website at Allurion - Events & Presentations.

A replay of the conference call will be available by telephone by dialing (800) 770-2030 and using Access Code 1905455. The archived webcast will also be available on Allurion’s Investor Relations website mentioned above.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Contacts

Global Media and Investor Inquiries
investors@allurion.com

Industry:

Allurion Technologies, Inc.

NYSE:ALUR
Release Versions
English
$Cashtags
$ALUR

Contacts

Global Media and Investor Inquiries
investors@allurion.com

More News From Allurion Technologies, Inc.

Allurion Advances Plan to Regain Listing Compliance

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (the “Company”) (OTCID: ALUR), a pioneer in metabolically healthy weight loss, announced today that it has appealed the decision by the New York Stock Exchange (the “NYSE”) to initiate delisting proceedings against Allurion’s securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least...

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced that it has officially begun training and on‑boarding partner accounts across the United States, including large academic medical centers and private practices. The company has begun manufacturing FDA-approved product and expects to begin shipping in April. This milestone represents a pivotal step in the company’s commercial expansion into the world’s larges...

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders’ equity or (ii) at le...
Back to Newsroom